Cell MedX Corp.|4Aug 24, 2:29 PM ET

ARNETT JEAN M 4

4 · Cell MedX Corp. · Filed Aug 24, 2018

Form 4

Period: 2016-09-26

DirectorVP, Corporate Strategy10% Owner

Transactions

Other
Stock Options (Right to Buy)
2016-09-26−1,250,000→ 0 total
Exercise: $0.05→ Common Stock (1,250,000 underlying)
Other
Stock Options (Right to Buy)
2016-09-26−1,250,000→ 0 total
Exercise: $0.05→ Common Stock (1,250,000 underlying)
Other
Stock Options (Right to Buy)
2016-09-26−1,250,000→ 0 total
Exercise: $0.05→ Common Stock (1,250,000 underlying)
Other
Stock Options (Right to Buy)
2016-09-26−2,500,000→ 0 total
Exercise: $0.05→ Common Stock (2,500,000 underlying)
Other
Stock Options (Right to Buy)
2016-09-26−2,500,000→ 0 total
Exercise: $0.05→ Common Stock (2,500,000 underlying)

Footnotes (6)

[F1]The Options were to vest upon the completion of first clinical trial and delivery of final white paper for the first clinical trial.
[F2]The Options were to vest upon the design and commencement of the second clinical trial.
[F3]The Options were to vest upon the completion of second clinical trial and delivery of final white paper for the second clinical trial.
[F4]The Options were to vest upon the design and commencement of the third clinical trial.
[F5]The Options were to vest upon the completion of the third clinical trial and delivery of final white paper for the third clinical trial.
[F6]Options that would have vested were to expire 5 years after vesting. Options that have not vested would have expired on 12/31/2019.

Documents

1 file